BMBarend M. Mol

Barend M. Mol

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Barend M. Mol has a total of 85 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Long-term risk of major adverse cardiovascular events after carotid endarterectomy—a 9-year prospective cohort study of the Athero-Express biobank

    by Barend M Mol, Carolijn J M de Bresser, P V de Kleijn, Ilonca Vaartjes, Gerard Pasterkamp, Michiel L Bots, Gert J de Borst, Michiel H F Poorthuis, Yvonne Koop

    Introduction: Carotid endarterectomy (CEA) is performed to lower the long-term risk of stroke in patients with carotid stenosis. Data evaluating long-term outcomes after CEA are scarce, but crucial for accurately determining long-term benefits. We aimed to estimate the long-term risk of major adverse cardiovascular and cerebrovascular events (MACE) after CEA. Patients and methods: A data linkage study was performed using patients from the Athero-Express biobank study who underwent CEA in two Dutch tertiary referral hospitals between 2002 and 2020. Data were linked to the Cause of Death Register, Population Register from Statistics Netherlands and the Hospital Discharge Register. The primary outcome was the occurrence of MACE at any time during follow-up and in the postprocedural (beyond 30 days) period. Results: CEA was performed in 2123 unique patients; linkage was possible for 1876. Median age was 70 years, 70% was male, and 87% had a symptomatic stenosis. MACE occurred in 455 patients (24.3%) during 9.2 years median follow-up. Five and 10-year cumulative incidence of MACE was 14.3% and 26.4%, respectively. Vascular death was the predominant contributor to MACE with 246 events (54.1%). Older age, current smoking, lower estimated glomerular filtration rate, diabetes mellitus and coronary artery disease (CAD) were associated with an increased risk of MACE. Preoperative antiplatelet use was associated with decreased risk of MACE. Patients with ischaemic stroke as qualifying event were at higher risk of MACE (P = .018). The incidence rate of MACE did not change over time (P = .9). Discussion: Patients remain at high risk of MACE after CEA, especially of vascular death and in older patients, current smokers and patients with diabetes or CAD. Conclusion: These findings underscore the need to enhance cardiovascular preventive strategies following CEA, in order to optimise long-term benefit.

  • Top Cited Papers
    Open Access

    Atherosclerotic Fibrous Plaques in Women Present ECM Remodeling Linked to TGF-β

    by Tim R. Sakkers, Eloi Mili, Hanna Winter, Daniek Kapteijn, R. Noah Perry, Nicolas Barbera, Kelsey Watts, Inês R. Dias, Denitsa Meteva, Marian Wesseling, et al.

    BACKGROUND: Sex and atherosclerotic plaque histology are intertwined, with fibrous plaques being more prevalent in women. Plaque erosion, a significant contributor to acute coronary syndromes, is linked to fibrous plaques and is more prevalent in women than men. We hypothesize that the molecular drivers of histologically determined fibrous plaques differ between men and women. METHODS: Human end-stage atherosclerotic plaques were isolated from carotid endarterectomy patients included in the Athero-Express Biobank. Fibrous plaques were histologically assessed, linked to clinical characteristics, and processed for protein, bulk RNA, single-cell RNA, and DNA methylation data. We leveraged sex-differential gene expression and deconvolution analyses to uncover sex-biased molecular and cellular mechanisms. Spatial transcriptomics localized gene expression patterns in plaques. Furthermore, we studied the female-biased processes in human plaque endothelial cells and vascular smooth muscle cells stimulated with TGF-β (transforming growth factor-β), with or without SMAD3 (SMAD family member 3) inhibition. RESULTS: Of 1889 atherosclerotic plaques (1309 male and 580 female), fibrous lesions were observed in 50% of female and 31% of male patients. Compared with patients with atheromatous plaques (n=494), women with fibrous plaques exhibited a high prevalence of smoking, while men with fibrous plaques presented more often with diabetes. Female fibrous plaques were characterized by smooth muscle cell–driven ECM (extracellular matrix) remodeling, TGF-β response, and endothelial-to-mesenchymal transition, localized to the fibrous cap. Conversely, male plaques were linked to macrophage-mediated inflammation proximal to the core, dependent on diabetes. Finally, we experimentally confirmed these female-biased mechanisms, showing that TGF-β induced endothelial-to-mesenchymal transition in endothelial cells and ECM remodeling in vascular smooth muscle cells, both partly reversed by SMAD3 inhibition. CONCLUSIONS: Women and men with end-stage fibrous atherosclerotic plaques exhibit distinct clinical and molecular profiles. These mechanisms might be candidate pathways to understand plaque erosion from a molecular point of view and may provide promising targets for atherosclerosis therapies, as they account for both sex and plaque phenotype.


  • Open Access

    Temporal trends in short- and long-term outcomes after carotid interventions for symptomatic or asymptomatic stenosis: a systematic review and meta-analysis

    by Carolijn J M de Bresser, Robbert B M Wiggers, Roos A M van Heeswijk, Barend M Mol, Fleur J W Knol, Gert J de Borst, Michiel H F Poorthuis

    Introduction: In meta-analyses of large cohorts, a decline in procedural risks after carotid endarterectomy (CEA) was found. It remains unclear whether these trends extent to smaller cohorts, carotid artery stenting (CAS), and how long-term outcomes have evolved. Patients and methods: PubMed and EMBASE were searched until 18 November 2024, for studies reporting on 100 or more adults undergoing CEA or CAS for symptomatic or asymptomatic carotid stenosis. Primary outcomes were 30-day and long-term risk of stroke or death. We performed separate analyses in smaller cohorts of < 500 patients. Results: 291 studies reported 475,266 patients undergoing CEA (214,526 symptomatic, 260,740 asymptomatic) and 209,117 undergoing CAS (77,133 symptomatic, 131,984 asymptomatic). Short-term stroke or death after CEA declined 36% (RR = 0.64, 95% CI, 0.63–0.64) per 5-year later treatment midyear in symptomatic and 41% (RR = 0.59, 95% CI, 0.59–0.59) in asymptomatic patients, with consistent trends in smaller cohorts.For CAS, short-term risks declined 44% (RR = 0.56, 95% CI, 0.53–0.58) in symptomatic, and 27% (RR = 0.73, 95% CI, 0.71–0.74) in asymptomatic patients, with consistent trends in smaller cohorts. Long-term death risk after CEA increased 26% (RR = 1.26, 95% CI, 1.20–1.32) and 11% in smaller cohorts. Long-term stroke risk after CAS increased 30% (RR = 1.30, 95% CI, 1.17–1.43) and 44% in smaller cohorts. Conclusions: Short-term risks after CEA and CAS have decreased over time, also in smaller cohorts. Long-term death after CEA and stroke after CAS have increased. The increased long-term risk of death after CEA and stroke after CAS limits the durability of carotid interventions and warrants further scrutiny.


  • Open Access

    Carotid Plaques Show More Unstable Characteristics Between 2010 and 2021 After a Prior Decade of Stabilization

    by Barend M. Mol, Tetiana Motsak, Joost K. R. Hoekstra, Gerard Pasterkamp, Gert J. de Borst, Dominique P. V. de Kleijn

    Background: Previously we reported a time‐dependent change in atherosclerotic carotid plaque characteristics, with decreasing destabilizing characteristics between 2002 and 2011. This observation was considered confirmative with a parallel improved adherence to medication and decrease in overall cardiovascular death in Western Europe. In the present study, we investigated whether these time‐dependent changes in plaque characteristics still occurred over the past decade. Methods: Using the Athero‐Express biobank, atherosclerotic plaques of 1277 consecutive patients undergoing carotid endarterectomy included between 2010 and 2021 were analyzed to examine time‐dependent changes in histological plaque characteristics in intervals of 2 years. These results were compared with our previous time‐dependent plaque composition data between 2002 and 2011 consisting of 1660 patients. Results: In contrast with the period 2002 through 2011, the period 2010 through 2021 showed a significant increase in vulnerable plaque characteristics: large lipid cores, intraplaque hemorrhage, macrophages, and calcification. When adjusted for confounders related to these plaque characteristics, such as time to operation and preoperative type of symptoms, the adjusted odds ratios per 2‐year increase in time were 1.204 (95% CI, 1.090–1.331; P P P 40% fat, and 1.366 (95% CI, 1.238–1.511; P <0.001) macrophages. Use of statins increased in both the 2002 through 2011 and 2010 through 2021 periods. Conclusions: Our study did not support a further increase in plaque‐stabilizing features in carotid atherosclerotic plaques between 2010 and 2021. In contrast, plaques even showed features of destabilization in the present cohort.


  • Open Access

    High Levels of Plasma and Plaque IsoDGR-Modified Fibronectin are Associated with Rupture Prone Plaque Characteristics in Carotid Endarterectomy Patients

    by Barend M. Mol, Tetiana Motsak, Joost K.R. Hoekstra, Valentina Osorio Zuluaga, Saskia Rumpff-Derksen, Ioanna Paspali-Strik, Sofong Cam Ngan, Gerard Pasterkamp, Gert J. de Borst, Siu Kwan Sze, et al.


  • Open Access

    Kynurenine and NAD+ Pathways are Associated with Macrophage Content and Polarization in Carotid Plaques

    by Charlotte J. Teunis, Lobke F. Zijlstra, Johannes H.M. Levels, Kasper T. Vinten, Maria M. Trętowicz, Barend Mol, Judith C. Sluimer, Michal Mokry, Andrew J. Murphy, Jeffrey Kroon, et al.

    Background and Aims: Metabolism dictates macrophage function and plays a central role in atherosclerotic plaque progression. The kynurenine pathway, which metabolizes the majority of the essential amino acid tryptophan, plays a pivotal role in regulating immune responses and supporting NAD+ synthesis, essential for cellular energy metabolism. Higher circulating kynurenine levels are associated with cardiovascular disease, yet their role in atherosclerotic plaques is unclear. This study aims to investigate the underlying mechanisms driving increased kynurenine concentrations in plaques and to determine whether kynurenine serves as a mere biomarker of low-grade inflammation or reflects specific macrophage-driven metabolic alterations that could position it as a potential therapeutic target. Methods: We used histological and transcriptomic data from two biobanks: the Athero Express Biobank (AE; n=91) and Maastricht human plaque study (MaasHPS, n= 26). Macrophages were identified through CD68 staining in AE, and M1/M2-like macrophage subtypes were distinguished by iNOS/CD68 and arginase/CD68 expression in MAASHPS. Primary human monocyte-derived cultured macrophages were polarized into M1- and M2-like phenotypes for using IFN-γ and IL-4, respectively. Tryptophan, kynurenine and/or NAD+ concentrations in plaques were quantified usingliquid chromatography and metabolomics analyses. Results: Kynurenine concentrations were significantly higher in plaques with greater macrophage density (p = 0.023). Transcriptomic analysis in AE revealed upregulation of IDO2, AFMID , and KYNU in plaques with increased macrophage infiltration (p < 0.05), but not IDO1 (p = 0.16). In the MAASHPS biobank, higher IDO1, KYNU , and KMO expression correlated negatively with M2 marker positive macrophages (p < 0.001), while HAAO correlated positively (p < 0.01). In vitro, M1-like macrophages showed increased IDO1 and reduced QPRT expression compared to M2-like macrophages. We found that this disruption in kynurenine pathway gene expression led to decreased NAD+ concentrations in M1-like macrophages compared to M2-like macrophages in vitro. Conclusion: Higher kynurenine levels in atherosclerotic plaques are increased by the increased presence of M1 macrophages, likely driven by both an increased IDO1 activity and reduced QPRT gene expression. This leads to decreased concentrations of NAD+, potentially determining the phenotype of the macrophages. Future studies should address whether modulation of the kynurenine pathway restores NAD+ metabolism and leads to a decrease in inflammation and an increased stable plaque phenotype.


  • Open Access

    Atherosclerotic fibrous plaques in females are characterized by endothelial-to-mesenchymal transition and linked to smoking

    by Tim R. Sakkers, Eloi Mili, Denitsa Meteva, Marian Wesseling, Daniek Kapteijn, Barend M. Mol, Gert J. de Borst, Dominique P.V. de Kleijn, Sander W. van der Laan, Mete Civelek, et al.

    Background: Sex and plaque histology are intertwined, with fibrous atherosclerotic plaques being more prevalent in women and pointing to general smooth muscle cell plasticity and estrogen signaling. Plaque erosion, a significant contributor to acute coronary syndromes (ACSs), is linked to fibrous plaques and is more prevalent in women as compared to men. We hypothesize that the molecular drivers of histologically determined fibrous plaques differ between men and women. Methods: Human end-stage atherosclerotic plaques were isolated from consecutive patients who underwent carotid endarterectomy and were included in the Athero-Express biobank. Fibrous plaques from both female and male patients were histologically assessed and further processed to obtain protein, bulk RNA, single-cell RNA and DNA methylation data. We leveraged sex-differential expression and deconvolution analyses to uncover sex-biased molecular mechanisms and cellular dynamics which were experimentally validated using an EndMT in vitro model. Results: Out of 1,889 atherosclerotic plaques (1,309 male and 580 female), fibrous lesions were observed in 50% of female (n=290) and 31% of male patients (n=416). Compared to patients with atheromatous plaques (n=494), women with fibrous plaques exhibited a higher prevalence of smoking (41% vs. 33%), while men with fibrous plaques presented more often with diabetes (29% vs. 20%). Transcriptional and proteomic phenotyping highlighted more immune-dependent and inflammatory processes in male fibrous plaques. Genes and proteins with higher abundance in female fibrous plaques pointed to endothelial-to-mesenchymal transition (EndMT) and extracellular matrix remodelling. Using single-cell RNA sequencing, we identified a dominant role of endothelial and smooth muscle cells in female plaques, and more macrophages in males. Finally, at the cellular level, we show that sex - specific, smoking-mediated promoter methylation changes may explain these differences. Conclusions: Patients with end-stage fibrous atherosclerotic plaques have a distinct clinical profile, with men more often having diabetes and women more often smoking. This clinical profile associates with sex differences that point to different cellular and molecular compositions of fibrous plaques. These mechanisms might be candidate pathways to understand plaque erosion from a molecular point of view and may provide promising targets for atherosclerosis therapies, as they account for the sex-specific differences in plaque phenotype. Graphical


  • Open Access

    Atherosclerotic Plaque Epigenetic Age Acceleration Predicts a Poor Prognosis and Is Associated With Endothelial-to-Mesenchymal Transition in Humans

    by Ernest Diez Benavente, Robin J.G. Hartman, Tim R. Sakkers, Marian Wesseling, Yannicke Sloots, Lotte Slenders, Arjan Boltjes, Barend M. Mol, Gert J. de Borst, Dominique P.V. de Kleijn, et al.

    BACKGROUND: Epigenetic age estimators (clocks) are predictive of human mortality risk. However, it is not yet known whether the epigenetic age of atherosclerotic plaques is predictive for the risk of cardiovascular events. METHODS: Whole-genome DNA methylation of human carotid atherosclerotic plaques (n=485) and of blood (n=93) from the Athero-Express endarterectomy cohort was used to calculate epigenetic age acceleration (EAA). EAA was linked to clinical characteristics, plaque histology, and future cardiovascular events (n=136). We studied whole-genome DNA methylation and bulk and single-cell transcriptomics to uncover molecular mechanisms of plaque EAA. We experimentally confirmed our in silico findings using in vitro experiments in primary human coronary endothelial cells. RESULTS: Male and female patients with severe atherosclerosis had a median chronological age of 69 years. The median epigenetic age was 65 years in females (median EAA, −2.2 [interquartile range, −4.3 to 2.2] years) and 68 years in males (median EAA, −0.3 [interquartile range, −2.9 to 3.8] years). Patients with diabetes and a high body mass index had higher plaque EAA. Increased EAA of plaque predicted future events in a 3-year follow-up in a Cox regression model (univariate hazard ratio, 1.7; P =0.0034) and adjusted multivariate model (hazard ratio, 1.56; P =0.02). Plaque EAA predicted outcome independent of blood EAA (hazard ratio, 1.3; P =0.018) and of plaque hemorrhage (hazard ratio, 1.7; P =0.02). Single-cell RNA sequencing in plaque samples from 46 patients in the same cohort revealed smooth muscle and endothelial cells as important cell types in plaque EAA. Endothelial-to-mesenchymal transition was associated with EAA, which was experimentally confirmed by TGFβ -triggered endothelial-to-mesenchymal transition inducing rapid epigenetic aging in coronary endothelial cells. CONCLUSIONS: Plaque EAA is a strong and independent marker of poor outcome in patients with severe atherosclerosis. Plaque EAA was linked to mesenchymal endothelial and smooth muscle cells. Endothelial-to-mesenchymal transition was associated with EAA, which was experimentally validated. Epigenetic aging mechanisms may provide new targets for treatments that reduce atherosclerosis complications.


  • Open Access

    Predictors of bleeding complications during catHeter-dirEcted thrombolysis for peripheral arterial occlusions (POCHET)

    by Barend M. Mol, Maarten C. Verwer, Rob Fijnheer, Jasper Florie, Oscar A. Groot, Falco Hietbrink, Mathilde Nijkeuter, Evert-Jan P. A. Vonken, Vincent van Weel, Dominique P. V. de Kleijn, et al.

    Introduction: The risk of major bleeding complications in catheter directed thrombolysis (CDT) for acute limb ischemia (ALI) remains high, with reported major bleeding complication rates in up to 1 in every 10 treated patients. Fibrinogen was the only predictive marker used for bleeding complications in CDT, despite the lack of high quality evidence to support this. Therefore, recent international guidelines recommend against the use of fibrinogen during CDT. However, no alternative biomarkers exist to effectively predict CDT-related bleeding complications. The aim of the POCHET biobank is to prospectively assess the rate and etiology of bleeding complications during CDT and to provide a biobank of blood samples to investigate potential novel biomarkers to predict bleeding complications during CDT. Methods: The POCHET biobank is a multicentre prospective biobank. After informed consent, all consecutive patients with lower extremity ALI eligible for CDT are included. All patients are treated according to a predefined standard operating procedure which is aligned in all participating centres. Baseline and follow-up data are collected. Prior to CDT and subsequently every six hours, venous blood samples are obtained and stored in the biobank for future analyses. The primary outcome is the occurrence of non-access related major bleeding complications, which is assessed by an independent adjudication committee. Secondary outcomes are non-major bleeding complications and other CDT related complications. Proposed biomarkers to be investigated include fibrinogen, to end the debate on its usefulness, anti-plasmin and D-Dimer. Discussion and conclusion: The POCHET biobank provides contemporary data and outcomes of patients during CDT for ALI, coupled with their blood samples taken prior and during CDT. Thereby, the POCHET biobank is a real world monitor on biomarkers during CDT, supporting a broad spectrum of future research for the identification of patients at high risk for bleeding complications during CDT and to identify new biomarkers to enhance safety in CDT treatment.


  • Open Access

    Diacylglycerols and Lysophosphatidic Acid, Enriched on Lipoprotein(a), Contribute to Monocyte Inflammation

    by Kim E. Dzobo, Arjen J. Cupido, Barend M. Mol, Lotte C.A. Stiekema, Miranda Versloot, Maaike Winkelmeijer, Jorge Peter, Anne-Marije Pennekamp, Stefan R. Havik, Frédéric M. Vaz, et al.

    BACKGROUND: Oxidized phospholipids play a key role in the atherogenic potential of lipoprotein(a) (Lp[a]); however, Lp(a) is a complex particle that warrants research into additional proinflammatory mediators. We hypothesized that additional Lp(a)-associated lipids contribute to the atherogenicity of Lp(a). METHODS: Untargeted lipidomics was performed on plasma and isolated lipoprotein fractions. The atherogenicity of the observed Lp(a)-associated lipids was tested ex vivo in primary human monocytes by RNA sequencing, ELISA, Western blot, and transendothelial migratory assays. Using immunofluorescence staining and single-cell RNA sequencing, the phenotype of macrophages was investigated in human atherosclerotic lesions. RESULTS: Compared with healthy individuals with low/normal Lp(a) levels (median, 7 mg/dL [18 nmol/L]; n=13), individuals with elevated Lp(a) levels (median, 87 mg/dL [218 nmol/L]; n=12) demonstrated an increase in lipid species, particularly diacylglycerols (DGs) and lysophosphatidic acid (LPA). DG and the LPA precursor lysophosphatidylcholine were enriched in the Lp(a) fraction. Ex vivo stimulation with DG(40:6) demonstrated a significant upregulation in proinflammatory pathways related to leukocyte migration, chemotaxis, NF-κB (nuclear factor kappa B) signaling, and cytokine production. Functional assessment showed a dose-dependent increase in the secretion of IL (interleukin)-6, IL-8, and IL-1β after DG(40:6) and DG(38:4) stimulation, which was, in part, mediated via the NLRP3 (NOD [nucleotide-binding oligomerization domain]-like receptor family pyrin domain containing 3) inflammasome. Conversely, LPA-stimulated monocytes did not exhibit an inflammatory phenotype. Furthermore, activation of monocytes by DGs and LPA increased their transendothelial migratory capacity. Human atherosclerotic plaques from patients with high Lp(a) levels demonstrated colocalization of Lp(a) with M1 macrophages, and an enrichment of CD68 + IL-18 + TLR4 + (toll-like receptor) TREM2 + (triggering receptor expressed on myeloid cells) resident macrophages and CD68 + CASP1 + (caspase) IL-1B + SELL + (selectin L) inflammatory macrophages compared with patients with low Lp(a). Finally, potent Lp(a)-lowering treatment (pelacarsen) resulted in a reduction in specific circulating DG lipid subspecies in patients with cardiovascular disease with elevated Lp(a) levels (median, 82 mg/dL [205 nmol/L]). CONCLUSIONS: Lp(a)-associated DGs and LPA have a potential role in Lp(a)-induced monocyte inflammation by increasing cytokine secretion and monocyte transendothelial migration. This DG-induced inflammation is, in part, NLRP3 inflammasome dependent.